RxDoctor Payments Data

Farrokh Khajavi Noori, MD

Psychiatry · Stoneham, MANPI 1073567749

Payments from drug & device makers

$7,067in general payments, 2019–2025

Across 339 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$793
  • Takeda Pharmaceuticals U.S.A., Inc.$674
  • Otsuka America Pharmaceutical, Inc.$569
  • AbbVie$565
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$6,98499%
  • Education$831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,067 in reported general payments places this provider in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts

Medicare billing

Part B allowed, 2024
$132,593
Medicare patients
129
Services billed
951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine16$159,528
TrintellixVortioxetine Hydrobromide35$28,040
RexultiBrexpiprazole13$21,718
Adderall XrDextroamphetamine/Amphetamine14$6,358
Lisdexamfetamine Dimesylate18$3,947
Fluphenazine Hcl18$3,019
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine105$2,470
Alprazolam198$2,434
Clonazepam224$2,281
Phenelzine Sulfate21$1,529
Lamotrigine51$1,325
Olanzapine50$1,164
Bupropion XlBupropion Hcl50$1,128
Mirtazapine72$1,110
Quetiapine Fumarate53$984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$793$159,52816 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$674$28,04035 claims
Otsuka America Pharmaceutical, Inc.Rexulti$569$21,71813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

Other psychiatry in Stoneham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →